The present invention pertains to a genetically modified saprotroph for the biotechnological production of erythritol and a method for the production of erythritol using said genetically modified saprotroph.

A method of producing para-hydroxybenzoic acid (pHBA) or a derivative thereof includes culturing the recombinant microorganism in a fermentation broth, wherein said recombinant microorganism comprising a genetically engineered pathway expressing at least one nucleic acid sequence encoding a polypeptide selected from: an exogenous chorismate pyruvate lyase of EC 5.4.4.2 or EC 4.1.3.40; an exogenous 3-deoxy-D-arabino-heptulosonate-7-phosphate (DAHP) synthase of EC 4.1.2.15, or EC 2.5.1.54; an exogenous shikimate kinase of EC 2.7.1.71; or an exogenous 3-dehydroquinate dehydratase (DHQ) of EC 4.2.1.10; adding a carbon source to the fermentation broth; and isolating the pHBA from the fermentation broth.

The systems and methods herein include engineering a host to produce psilocybin using engineered enzymes, genetic changes, and exogenous psilocybin precursor addition (e.g., addition of L-tryptophan to a growing culture of a psilocybin producing recombinant host strain). The process occurs in genetically engineered host cell(s) that can produce psilocybin.

The present disclosure relates to a microorganism for producing a mycosporine-like amino acid, and a method for producing a mycosporine-like amino acid using the microorganism. The microorganism of the present disclosure shows an improved ability for producing a mycosporine-like amino acid and thus can be effectively used in the production of a mycosporine-like amino acid.

The systems and methods herein include engineering a host to produce psilocybin using engineered enzymes, genetic changes, and exogenous psilocybin precursor addition (e.g., addition of L-tryptophan to a growing culture of a psilocybin producing recombinant host strain). The process occurs in genetically engineered host cell(s) that can produce psilocybin.

The present disclosure is directed to methods for proteome engineering cells such that cell-free extracts prepared from such engineered cells can be modified to have metabolic flux directed to a metabolism of interest. In addition, methods for producing cell-free extracts with directed metabolism, cell-free extracts and kits that contain cell-free extracts are also disclosed.

The present disclosure relates to a microorganism producing a mycosporine-like amino acid and a method for producing a mycosporine-like amino acid using the microorganism.

Since the microorganism of the present disclosure has an increased mycosporine-like amino acid-producing ability, it can be effectively used in producing mycosporine-like amino acids.

Provided is a transformant of a microorganism that has improved catechol productivity.

The present disclosure describes the engineering of microbial cells for fermentative production of tyramine and provides novel engineered microbial cells and cultures, as well as related tyramine production methods.

The systems and methods herein include engineering a host to produce psilocybin using engineered enzymes, genetic changes, and exogenous psilocybin precursor addition (e.g., addition of L-tryptophan to a growing culture of a psilocybin producing recombinant host strain). The process occurs in genetically engineered host cell(s) that can produce psilocybin.